AMP-K

AMP-activated protein kinase (AMPK) is a conserved, heterotrimeric serine/threonine kinase composed of a catalytic alpha subunit and regulatory beta and gamma subunits. The kinase functions as a master cellular energy sensor. When intracellular AMP levels rise relative to ATP — during metabolic stress, nutrient deprivation, hypoxia, or vigorous exercise — AMP binds the gamma subunit, triggering phosphorylation of threonine-172 on the alpha subunit by the upstream kinase LKB1 (STK11) while protecting the activated enzyme against inactivating phosphatases.

Once active, AMPK simultaneously upregulates energy-producing catabolic pathways and suppresses energy-consuming anabolic processes. Catabolic effects include stimulation of fatty acid beta-oxidation (via ACC phosphorylation), mitochondrial biogenesis through PGC-1alpha coactivation, and GLUT4-mediated glucose uptake in skeletal muscle. Anabolic suppression targets lipid synthesis and protein synthesis via mTORC1 inhibition.

In immune cells, AMPK exerts distinct immunoregulatory actions. In macrophages, AMPKalpha1 activation suppresses pro-inflammatory M1 polarization and promotes the anti-inflammatory M2 phenotype by inhibiting NF-kappaB signaling through SIRT1 and CREB upregulation, reducing mTORC1-dependent IL-6 and IL-12 production, and limiting prostaglandin E2 and nitric oxide synthesis. In regulatory T cells, AMPK sustains mitochondrial mass and aerobic respiration capacity under metabolically stressed microenvironments such as solid tumors and virally inflamed lung tissue.

The preponderance of evidence for AMPK's metabolic and immune effects derives from preclinical cell culture and rodent experiments. Controlled human clinical data for AMPK-targeting peptides is absent, and evidence specifically for immune support remains limited to mechanistic and translational studies.

The most direct peptide evidence comes from Chapnik and colleagues (Journal of Endocrinology, 2014), who synthesized two peptides — Myr-GHVPTLFKKIRG-NH2 and Ac-GHVPTLFKKIRG-NH2 — mimicking the alphaG region of the alpha2 AMPK catalytic domain. In diet-induced obese C57BL/6 mice (n=10 per group), 12 days of subcutaneous injection significantly reduced fasting blood glucose, body weight, adipose tissue weight, insulin, triglycerides, and total cholesterol. A critical finding was that liver weight and hepatic lipid content increased substantially because the peptides failed to activate AMPK in hepatocytes, demonstrating a tissue-specificity hazard.

Sag et al. (J Immunology, 2008) demonstrated in murine and human monocyte-derived macrophages that AICAR-mediated AMPK activation promoted M2 polarization and suppressed LPS-triggered pro-inflammatory cytokines. Phair et al. (Molecular Metabolism, 2022) provided genetic confirmation: AMPKalpha1 knockout bone marrow-derived macrophages showed striking M1 hyperpolarization upon LPS challenge, with roughly 10-fold increases in IL-1alpha/beta and marked elevations in prostaglandin E2 and nitric oxide.

Bone et al. (Scientific Reports, 2021) provided the most clinically adjacent human data: metformin, an indirect AMPK activator, reversed impaired bacterial killing in leukocytes taken ex vivo from four post-sepsis shock survivors and improved Pseudomonas aeruginosa clearance in a murine cecal ligation and puncture model.

AICAR (acadesine), the most clinically evaluated AMPK activator, completed Phase II/III trials for cardiac surgery (RED-CABG, 2012 — no mortality benefit) and a 2013 Phase II CLL trial identifying 210 mg/kg IV as the optimal biological dose with acceptable tolerability. None of these trials evaluated immune support as a primary endpoint. No completed randomized controlled trials exist for AMPK-activating peptides specifically for immune support in humans.

Typical dosage: 100-200 mg (daily).

No regulatory-approved dosing exists for AMPK-targeting peptides for metabolic or immune indications. The following reflects data from research models only.

In the Chapnik et al. (2014) mouse study, AMPK-derived peptides were administered by subcutaneous injection daily for 12 consecutive days in obese mice; specific per-kilogram doses were not prominently reported in available summaries, and no dose-response relationship or minimum effective dose was established.

AICAR (acadesine), the most clinically studied AMPK-activating compound in humans, has been evaluated intravenously at 50 to 315 mg/kg in clinical trials across cardiac surgery and oncology indications. Oral bioavailability is below 5 percent, rendering non-intravenous formulations ineffective at pharmacologically active exposures.

Metformin, an indirect AMPK activator approved for type 2 diabetes, is typically dosed orally at 500 to 2000 mg per day in divided doses; its AMPK-mediated immune effects at these doses have not been confirmed by controlled trials designed around immune endpoints.

Natural AMPK activators such as berberine (commonly 500 mg two to three times daily) and resveratrol (100 to 500 mg per day) are used in community and self-experimentation contexts, but their immune benefits mediated specifically through AMPK in humans remain unproven.

This information is provided for educational and research reference purposes only and does not constitute medical advice. AMPK-targeting peptides have not received FDA approval for immune or metabolic support indications; consult a qualified healthcare provider before using any such compound.

No compound-specific stability data has been identified for this peptide. The general lyophilized-peptide handling framework applies — see Storage & handling for temperature, reconstitution diluent, and beyond-use dating principles.

Preclinical murine tumor models are the principal source of combination data. Pharmacological AMPK activation has been shown to synergize with anti-PD-1 and anti-CTLA-4 immune checkpoint inhibitors to enhance antitumor immunity in mice, in part by downregulating PD-1 expression on regulatory T cells via the HMGCR/p38 signaling axis (Jiang et al., PMC8515644, 2021). These findings have not been tested in human oncology trials and must be considered preclinical only.

Combination with physical exercise is supported by mechanistic rationale, as exercise is a potent physiological AMPK activator, and observational and animal data suggest additive effects when paired with polyphenol bioactives such as berberine, quercetin, or resveratrol. Human evidence for synergistic immune benefit from these pairings is anecdotal.

Metformin has been studied alongside other glucose-lowering agents in diabetes management but not specifically for combined immune co-benefits. Some investigators have proposed co-administration of AICAR with selective direct AMPK agonists in research settings to control for AMPK-independent off-target effects, though this has no established clinical application.

All combination strategies for AMPK-targeting peptides and immune support are speculative or based on animal model inference; none has been validated by human clinical trials.

AMP-K is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.

PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.

Reported side effects: Generally safe

No formal human safety profile exists for synthetic AMPK-targeting peptides used for immune or metabolic support indications. Available data derives from preclinical models and clinical trials of chemically distinct AMPK activators.

Animal studies by Chapnik et al. (2014) identified paradoxical hepatic steatosis as a tissue-selectivity risk: AMPK-derived peptides that activated the kinase in skeletal muscle and adipose tissue while failing to activate it in hepatocytes caused substantial liver fat accumulation despite producing systemic metabolic improvements. This finding is a meaningful safety signal for any tissue-selective AMPK activator.

AICAR, the most clinically evaluated AMPK activator, produced the following adverse effects in human trials: mild hyperuricemia (common, generally non-serious), transient hypoglycemia, infusion-related hypotension, transient anemia and thrombocytopenia, and dose-dependent renal impairment. A 2019 Phase II trial in myelodysplastic syndrome was discontinued due to serious renal toxicities at high doses.

A mechanistic concern identified by Cui et al. (2023) is that excessive or uncontrolled AMPK activation may shift autophagy from a cytoprotective to a cytotoxic program (autophagic cell death), with potential adverse consequences for rapidly proliferating immune effector cell populations.

Metformin as an indirect activator produces primarily gastrointestinal side effects (nausea, diarrhea) and rare lactic acidosis in patients with impaired renal clearance; these effects are not directly generalizable to synthetic AMPK peptides. In the absence of human safety trial data for AMPK peptides specifically, formal contraindication lists do not exist. Caution is warranted in individuals with hepatic or renal disease given evidence from adjacent compounds.